Prostatic Tissual Distribution of Alfuzosin in Patients with Benign Prostatic Hyperplasia Following Repeated Oral Administration

Author： Mottet N.   Bressolle F.   Delmas V.   Robert M.   Costa P.  

Publisher： Elsevier

ISSN： 0302-2838

Source： European Urology, Vol.44, Iss.1, 2003-07, pp. : 101-105

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-Term Safety and Efficacy of a Once-Daily Formulation of Alfuzosin 10 mg in Patients with Symptomatic Benign Prostatic Hyperplasia: Open-Label Extension Study

By van Kerrebroeck P.   Jardin A.   van Cangh P.   Laval K.U.   The ALFORTI Study Group  

European Urology, Vol. 41, Iss. 1, 2002-01 ,pp. : 54-61

Elsevier

Access to resources Recommend Favorite

Nocturia and benign prostatic hyperplasia

By Yoshimura K.   Ohara H.   Ichioka K.   Terada N.   Matsui Y.   Terai A.   Arai Y.  

Urology, Vol. 61, Iss. 4, 2003-04 ,pp. : 786-790

Elsevier

Access to resources Recommend Favorite

First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia

By Marks L.S.   Roehrborn C.G.   Gittelman M.   Kim D.   Forrest J.   Jacobs S.  

Urology, Vol. 62, Iss. 5, 2003-11 ,pp. : 888-893

Elsevier

Access to resources Recommend Favorite

Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results

By Lukacs B.   Leplegrave ge A.   Thibault P.   Jardin A.  

Urology, Vol. 48, Iss. 5, 1996-11 ,pp. : 731-740

Elsevier

Access to resources Recommend Favorite

Temperature-correlated histopathologic changes following microwave thermoablation of obstructive tissue in patients with benign prostatic hyperplasia

By Larson T.R.   Bostwick D.G.   Corica A.  

Urology, Vol. 47, Iss. 4, 1996-04 ,pp. : 463-469

Elsevier

Access to resources Recommend Favorite